
Jiangsu Hengrui Pharmaceuticals reported a 20.55 per cent revenue increase to 8.95 billion yuan for the third quarter, surpassing analyst expectations driven by strong innovative drug sales and out-licensing revenue.
AI-generated summary
Jiangsu Hengrui Pharmaceuticals is a major Chinese drug manufacturer focusing on innovative drug development.
Jiangsu Hengrui Pharmaceuticals, one of China’s largest drug makers, reported a 20.55 per cent rise in third-quarter revenue to 8.95 billion yuan (US$1.34 billion), beating analyst estimates of 8.55 billion yuan amid stronger innovative drug sales.
Net profit reached 2.46 billion yuan for the three months ended September 30, jumping 88.92 per cent year on year and exceeding the Bloomberg analyst consensus estimate of 2.38 billion yuan.
Improving innovative drug sales and out-licensing revenue contributed to the growth, the company said in a Tuesday filing.

Xinxing Electronics, a major IC substrate manufacturer, announced today that its board of directors has decided to dispose of the entire equity of its Japanese subsidiary UNIMICRON JAPAN and has signed a letter of intent for equity transfer with MEIKO ELECTRONICS to facilitate the group's overall business planning and employee career development.

Wood, the founder of Ark Investment, recently adjusted his shareholdings, selling about US$22.5 million worth of AMD and TSMC stocks, and investing about US$6.8 million to buy Archer Aviation and Joby Aviation, showing that funds are shifting from semiconductors to the emerging electric air taxi industry.

On the 27th, Taiwan Itochu announced the transfer of its 17.27% stake in Taipei 101 to Chengmei Venture Capital, a subsidiary of the Wei family of Ting Hsin Group. This transaction enables the Wei family to return to Taipei 101 and become the single largest private shareholder of the building. Wei Yingjiao's office stated that it will support the management team as a financial investor.

HSBC Holdings released its third quarter results for 2026. The profit before tax during the period was approximately US$9.6 billion, a year-on-year increase of 32%. Total revenue reached $18.6 billion. Wealth management and wholesale transaction banking have become growth drivers, and the group expects net interest income from its banking business to be no less than US$46 billion for the full year.

Itochu Taiwan announced that it will transfer all of its approximately 17.27% stake in Taipei 101 to Chengmei Venture Capital, a subsidiary of the Wei family of Ting Hsin Group. Taipei 101 respects this and welcomes new shareholders to join, emphasizing that it will continue to promote the company's steady growth.

The second phase of the 140th Canton Fair was held in Guangzhou. The event focused on "green time and space" and discussed the construction of modular booths. Exhibitors shared their experiences with the trading group, pointing out that modular construction has the advantages of cost reduction, efficiency increase, recycling and shortening of construction period, etc., and is promoting the transformation of the convention and exhibition industry into a green and low-carbon normalization.